Back to top
more

Corcept Therapeutics (CORT)

(Real Time Quote from BATS)

$46.40 USD

46.40
90,520

-0.35 (-0.75%)

Updated Oct 2, 2024 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Roche Reports Positive Data From Tecentriq Combination Study

Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

    Alnylam Starts Rolling NDA Submission for RNAi Candidate

    Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

      Incyte (INCY) Initiates Essential Thrombocythemia Trial

      Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

        Valeant (VRX) Announces Pricing of Senior Secured Notes

        Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.

          Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

          Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

            Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

            Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.

              Cardinal Health (CAH) to Divest Assets to Shanghai Pharma

              Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.

                Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                  Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

                  Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

                    Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

                    GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.

                      The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics

                      The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics

                        Nilanjan Choudhury headshot

                        5 Stocks That Doubled in 2017 and Can Keep Soaring Higher

                        The strong stock rally does not necessarily indicate that all scrips would be wise picks.

                          Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

                          Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

                            Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe

                            Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.

                              Top Ranked Momentum Stocks to Buy for August 29th

                              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 29th:

                                Mylan and Otsuka Ink Agreement to Commercialize Deltyba

                                Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.

                                  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

                                  Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

                                    BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

                                    BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

                                      Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View

                                      Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.

                                        Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge

                                        Corcept Therapeutics (CORT) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

                                          Can The Uptrend Continue for Corcept Therapeutics (CORT)?

                                          Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance

                                            Top Ranked Momentum Stocks to Buy for August 7th

                                            Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:

                                              Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session

                                              Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.

                                                Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised

                                                Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.

                                                  Vertex (VRTX) Triple Combination CF Studies Data Positive

                                                  Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.